BioSpace News Archive

Millar, Inc., medical device manufacturer and OEM pressure sensor integration partner, today announced the appointment of Dr. Alfred Coats as Chairman of the Board for Millar, Inc.

Inc. magazine today revealed that Scientist.com, the world’s largest enterprise marketplace for outsourced R&D services, ranked no. 289 on its Inc. 5000 list, the prestigious ranking of the nation’s fastest-growing private companies.

Centene Corporation (NYSE: CNC) announced today it will present at the Wells Fargo Securities 2019 Healthcare Conference, to be held September 4-5, at the Westin Copley Plaza in Boston.

Two experienced healthtech industry leaders today announced the launch of MDisrupt, the first medical diligence company for the healthtech industry.

Vyntus™ ONE, Vyntus™ BODY and SentrySuite™ Software Available to U.S. Healthcare Market Immediately

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for peginterferon lambda (Lambda) for the treatment of hepatitis delta virus (HDV) infection.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.

Advanced BioNutrition (ABN) and GreenLight Biosciences (GreenLight) announce today a collaboration to develop high stability RNA products for specific agriculture applications.

Heron Therapeutics, Inc. (Nasdaq: HRTX), today announced that the results from EPOCH 2, a Phase 3 study of the investigational agent HTX-011 in open inguinal hernia repair surgery with mesh, have been published in the journal, Hernia, in an article entitled “HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study.”

HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular process development, today announced operational highlights and financial results for the six months ended June 30, 2019.